Search Medical Condition
Please enter condition
Please choose location

Hardwick,, United Kingdom Clinical Trials

A listing of Hardwick,, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (130) clinical trials

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

The purpose of study is to test whether rivaroxaban added to standard of care treatment, when compared to placebo, has the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute ...

Phase

3.93 miles

Learn More »

This study is designed to evaluate progression-free survival for ACE-196 vs ibrutinib in previously treated chronic lymphocytic leukemia. Intervention: ACP-196 will be orally administered until disease progression or unacceptable toxicity. Ibrutinib will be orally administered until disease progression or unacceptable toxicity. Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: ...

Phase

4.14 miles

Learn More »

The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

Phase

4.14 miles

Learn More »

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis

This is a prospective, observational, cohort study to collect data on adult participants who have a confirmed diagnosis of psoriatic arthritis (PsA) and are starting either STELARA or a new TNFi as a new therapy in a first, second, or third line of biologic disease-modifying antirheumatic drug (bDMARD) therapy. Approximately ...

Phase N/A

4.52 miles

Learn More »

Cambridge Brain Mets Trial 1

Brain metastases occur in 20-40% of all patients with cancer, with an incidence 10 times higher than that of primary malignant brain tumours. patients with brain metastases are an underserved population. Overall they have a poor prognosis with a median survival of 1-2 months with corticosteroids and only 5-7 months ...

Phase

4.52 miles

Learn More »

Surgery in Treating Patients With Neuroblastoma

OBJECTIVES: - Evaluate the safety and efficacy of surgical treatment alone for stage II neuroblastoma without N-myc amplification (NMA). - Describe predictive factors of relapse and survival for stages I and II neuroblastoma without NMA treated by surgery alone. OUTLINE: Patients with localized resectable tumors undergo surgery. Postoperative evaluations are ...

Phase

4.52 miles

Learn More »

Combination Chemotherapy With or Without Filgrastim Before Surgery High-Dose Chemotherapy and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

OBJECTIVES: - Compare the efficacy of myeloablative therapy with busulfan and melphalan vs carboplatin, etoposide, and melphalan, in terms of 3- and 5-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS), in patients with high-risk neuroblastoma. - Compare the 3-year EFS in these patients treated with isotretinoin with ...

Phase

4.52 miles

Learn More »

MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer

OBJECTIVES: Primary - To establish whether bevacizumab-induced changes in dynamic contrast-enhanced (DCE)-MRI vascular parameters are significantly enhanced by recombinant interferon alpha-2a. - To establish whether there is an interferon alpha-2a dose response in potentiating bevacizumab-induced changes in DCE-MRI vascular parameters. Secondary - To correlate changes in DCE-MRI vascular parameters for ...

Phase

4.52 miles

Learn More »

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

OBJECTIVES: - Investigate inter-individual variability in the pharmacokinetics of selected anticancer drugs in infants and children age < 2 years on current dosing schedules. - Compare drug exposures and degree of pharmacokinetic variability in children < 2 years with data obtained from published studies in older children. - Relate inter-individual ...

Phase N/A

4.52 miles

Learn More »

Pharmacokinetics of Dactinomycin in Young Patients With Cancer

OBJECTIVES: - Determine the pharmacokinetics (PKs) of dactinomycin in pediatric patients with cancer. - Determine the degree of interpatient variation in the PKs of this drug. - Determine the influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs in these patients. - Correlate drug PKs ...

Phase N/A

4.52 miles

Learn More »